Home Nav
Nextech Invest Logo

Jakob Loven

Alfred Scheidegger

Prior to joining Nextech Invest as Partner in 2017, Jakob Loven, PhD, was a senior associate and strategic adviser at Third Rock Ventures in Cambridge, USA, a venture capital firm specialized in early stage healthcare investments. Dr Loven is an accomplished oncology-focused entrepreneur and life sciences venture capitalist. He co-founded in 2016 Relay Therapeutics in Cambridge, USA, and is also one of the scientific founders of Syros Pharmaceuticals, a biotechnology company launched in 2013 in Cambridge, USA. Dr Loven has completed his postdoctoral training at the Whitehead Institute for Biomedical Research in Cambridge, USA, where his work provided the foundational intellectual property of Syros Pharmaceuticals. He holds a PhD in Medical Sciences from the Karolinska Institutet in Stockholm, Sweden, and a BSc in in Natural Sciences from the University of Cambridge, England.

Mr. Loven is responsible for the following Nextech portfolio companies:



59th ASH Annual Meeting

09.12. – 12.12.2017

Atlanta, USA

  • 13.11.2017

    Jounce Therapeutics reports third quarter 2017 financial...

  • 13.11.2017

    Tracon Pharmaceuticals announces positive results from...

  • 10.11.2017

    Blueprint Medicines announces new data from ongoing...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.